Gregory Miller is the founder of Transition Bio. Transition Bio has raised $50M in total funding. Latest round: Series A. Based in Cambridge, MA.
Gregory Miller is the former CEO of Transition Bio, a joint spin-out from Harvard University and the University of Cambridge focused on biomolecular condensate drug discovery. As CEO, he secured the company's $50 million Series A financing and expanded its scientific leadership team. He is now the CEO of Parabilis Medicines.
Full founder directory · Investor directory · Company funding database · Fundraising library